vs

Side-by-side financial comparison of Fangdd Network Group Ltd. (DUO) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $28.4M, roughly 1.3× Fangdd Network Group Ltd.). Fangdd Network Group Ltd. runs the higher net margin — -18.7% vs -304.2%, a 285.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 47.4%).

Fangdd Network Group Ltd. operates a leading digital real estate service platform in China, offering property listing, transaction matching, home furnishing consultation and operational support for buyers, sellers, agents and real estate development enterprises across multiple domestic city tiers.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

DUO vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.3× larger
RXRX
$35.5M
$28.4M
DUO
Growing faster (revenue YoY)
RXRX
RXRX
+634.3% gap
RXRX
681.7%
47.4%
DUO
Higher net margin
DUO
DUO
285.5% more per $
DUO
-18.7%
-304.2%
RXRX

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
DUO
DUO
RXRX
RXRX
Revenue
$28.4M
$35.5M
Net Profit
$-5.3M
$-108.1M
Gross Margin
9.1%
59.8%
Operating Margin
-35.3%
-304.8%
Net Margin
-18.7%
-304.2%
Revenue YoY
47.4%
681.7%
Net Profit YoY
-322.5%
39.6%
EPS (diluted)
$-1.35
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DUO
DUO
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$5.2M
Q2 25
$28.4M
$19.2M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$19.3M
$14.4M
Q1 24
$13.8M
Net Profit
DUO
DUO
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-162.3M
Q2 25
$-5.3M
$-171.9M
Q1 25
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$2.4M
$-97.5M
Q1 24
$-91.4M
Gross Margin
DUO
DUO
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
9.1%
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
12.5%
36.2%
Q1 24
19.1%
Operating Margin
DUO
DUO
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-35.3%
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-49.0%
-697.4%
Q1 24
-698.4%
Net Margin
DUO
DUO
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-3135.3%
Q2 25
-18.7%
-894.2%
Q1 25
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
12.4%
-676.6%
Q1 24
-662.4%
EPS (diluted)
DUO
DUO
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-1.35
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DUO
DUO
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$24.9M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$53.1M
$1.1B
Total Assets
$94.8M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DUO
DUO
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$24.9M
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$18.9M
$474.3M
Q1 24
$296.3M
Total Debt
DUO
DUO
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
DUO
DUO
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$53.1M
$919.1M
Q1 25
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$29.4M
$584.4M
Q1 24
$401.2M
Total Assets
DUO
DUO
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.4B
Q2 25
$94.8M
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$92.7M
$775.9M
Q1 24
$557.8M
Debt / Equity
DUO
DUO
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DUO
DUO
RXRX
RXRX
Operating Cash FlowLast quarter
$-3.0M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DUO
DUO
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-117.4M
Q2 25
$-3.0M
$-76.4M
Q1 25
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-808.0K
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
DUO
DUO
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-957.0K
$-83.4M
Q1 24
$-109.0M
FCF Margin
DUO
DUO
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-5.0%
-578.5%
Q1 24
-789.9%
Capex Intensity
DUO
DUO
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
0.8%
8.2%
Q1 24
48.2%
Cash Conversion
DUO
DUO
RXRX
RXRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-0.34×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons